- Investing Ideas
- Swedish Pharmaceuticals & Biotech Healthy high growth potential
Swedish Pharmaceuticals & Biotech Healthy high growth potential
Results
8
Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.
8 companies
Camurus
Market Cap: SEK 36.6b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMX
SEK 615.00
7D
-1.8%
1Y
-12.5%
Bonesupport Holding
Market Cap: SEK 14.8b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEX
SEK 224.40
7D
0.4%
1Y
-24.2%
BioArctic
Market Cap: SEK 30.6b
Develops biological drugs for patients with central nervous system disorders in Sweden.
BIOA B
SEK 345.00
7D
6.9%
1Y
29.2%
Genovis AB (publ.)
Market Cap: SEK 1.4b
Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia.
GENO
SEK 20.15
7D
2.9%
1Y
-20.5%
Egetis Therapeutics
Market Cap: SEK 3.7b
A pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally.
EGTX
SEK 7.87
7D
12.1%
1Y
49.3%
Moberg Pharma
Market Cap: SEK 504.8m
A pharmaceutical company, develops and commercializes medical products primarily in Sweden.
MOB
SEK 10.70
7D
-6.1%
1Y
30.5%
AlzeCure Pharma
Market Cap: SEK 882.5m
Operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system.
ALZCUR
SEK 6.40
7D
-4.8%
1Y
75.8%
Isofol Medical
Market Cap: SEK 269.2m
Operates as a clinical stage biotech company.
ISOFOL
SEK 0.84
7D
2.7%
1Y
-2.6%